GSK takes option to develop T-cell therapy with Adaptimmune – pharmaphorum
pharmaphorum |
GSK takes option to develop T–cell therapy with Adaptimmune
pharmaphorum Novartis just got the first chimeric antigen receptor T–cell (CAR-T) therapy approved in the US, and Gilead has swooped with a $12 billion bid to acquire Kite Pharma, which has a rival T–cell therapy under review in the US and Europe. Adaptimmune will … GSK wants in on Adaptimmune's Adaptable T cell Cancer Treatment |
